apixaban + andexanet alfa

This combination involves the use of **apixaban**, an oral direct **Factor Xa inhibitor** anticoagulant, together with **andexanet alfa**, a recombinant modified human Factor Xa protein that acts as a specific reversal agent for apixaban-induced anticoagulation. Apixaban is used primarily for stroke prevention in atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). When there is *life-threatening or uncontrolled bleeding* in patients on apixaban, andexanet alfa is administered intravenously to rapidly reverse apixaban’s anticoagulant effect. Andexanet alfa acts as a decoy for factor Xa inhibitors, binding apixaban and neutralizing its activity, thus restoring thrombin generation and normal coagulation. Andexanet alfa is indicated for emergency use to reverse the anticoagulation effects of apixaban and is not itself an anticoagulant[1][2][3][4].

Brand names

Eliquis (apixaban)Andexxa (andexanet alfa)Ondexxya (andexanet alfa)

Other names

apixaban + andexanet alfa